key: cord-1015691-5wh7dviu
authors: Bai, Francesca; Tomasoni, Daniele; Falcinella, Camilla; Barbanotti, Diletta; Castoldi, Roberto; Mulè, Giovanni; Augello, Matteo; Mondatore, Debora; Allegrini, Marina; Cona, Andrea; Tesoro, Daniele; Tagliaferri, Gianmarco; Viganò, Ottavia; Suardi, Elisa; Tincati, Camilla; Beringheli, Tomaso; Varisco, Benedetta; Battistini, Chiara Luridiana; Piscopo, Kyrie; Vegni, Elena; Tavelli, Alessandro; Terzoni, Stefano; Marchetti, Giulia; Monforte, Antonella d’Arminio
title: Female gender is associated with “long COVID” syndrome: a prospective cohort study
date: 2021-11-09
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.11.002
sha: 155010ca7c7727ea0bfe6e975d6e6d0e264be78b
doc_id: 1015691
cord_uid: 5wh7dviu

OBJECTIVE: We explored the association between female gender and “long COVID” syndrome, defined as persistence of physical and/or psychological symptoms for more than 4 weeks after recovery from acute COVID-19 disease. Secondary aim was to identify predictors of “long COVID” syndrome by multivariable logistic regression analysis. METHODS: This is a single-centre prospective cohort study conducted at San Paolo Hospital in Milan, Italy. We enrolled adult patients that were evaluated at the post-COVID outpatient service of our Infectious Diseases Unit between April 15(th) 2020 and December 15(th) 2020. Participants were individuals who had clinically recovered from COVID-19 and in whom virological clearance had occurred. Previous infection by SARS-CoV-2 was microbiologically documented by positivity at reverse-transcriptase polymerase chain reaction (RT-PCR) assay of nasopharyngeal swab. All enrolled patients underwent blood tests and a comprehensive medical examination at follow-up. Individuals were interviewed about resolved and persisting symptoms and were asked to fill in two questionnaires to allow assessment of the Hospital Anxiety and Depression symptoms (HADS) score and of the Impact of Event Scale–Revised (IES-R) score. RESULTS: A total of 377 patients were enrolled in the study. The median time from symptom onset to clinical recovery and virological clearance was 79 (IQR 69-102) and 56 (IQR 47-74) days, respectively. A diagnosis of “long COVID” syndrome was made in 260/377 (69%) patients. The most common reported symptoms were fatigue (149/377, 39.5%), exertional dyspnoea (109/377, 28.9%), musculoskeletal pain (80/377, 21.2%) and “brain fog” (76/377, 20.2%). Anxiety symptoms were ascertained in 71/377 (18.8%) individuals, whereas 40/377 (10.6%) patients presented symptoms of depression. Post-traumatic stress disorder (defined by a pathological IES-R score) was diagnosed in one-third of patients (85/275, 31%). Female gender was independently associated with “long COVID” syndrome at multivariable analysis (AOR 3.3 versus males, 95%CI 1.8-6.2, p<0.0001). Advanced age (AOR 1.03 for 10 years older, 95%CI 1.01-1.05, p=0.01) and active smoking (AOR 0.19 for former smokers vs active smokers, 95%CI 0.06-0.62, p=0.002) were also associated with a higher risk of “long COVID”, while no association was found between severity of disease and “long COVID” (AOR 0.67 for Continuous Positive Airway Pressure [CPAP]/Non-Invasive Mechanical Ventilation [NIMV]/Orotracheal Intubation [OTI] vs no 02 therapy, 95%CI 0.29-1.55, p=0.85). CONCLUSION: Factors that were found to be associated with a higher risk of developing “long COVID” syndrome were female gender and active smoking, but not severity of the acute disease. Individuals affected by SARS-CoV-2 infection with the aforementioned features should be early identified and involved in follow-up programs.

We explored the association between female gender and "long COVID" syndrome, defined as persistence of physical and/or psychological symptoms for more than 4 weeks after recovery from acute COVID-19 disease. Secondary aim was to identify predictors of "long COVID" syndrome by multivariable logistic regression analysis.

This is a single-centre prospective cohort study conducted at San Paolo Hospital in Milan, Italy. We enrolled adult patients that were evaluated at the post-COVID outpatient service of our Infectious Diseases Unit between April 15 th 2020 and December 15 th 2020. Participants were individuals who had clinically recovered from COVID-19 and in whom virological clearance had occurred. Previous infection by SARS-CoV-2 was microbiologically documented by positivity at reverse-transcriptase polymerase chain reaction (RT-PCR) assay of nasopharyngeal swab. All enrolled patients underwent blood tests and a comprehensive medical examination at follow-up. Individuals were interviewed about resolved and persisting symptoms and were asked to fill in two questionnaires to allow assessment of the Hospital Anxiety and Depression symptoms (HADS) score and of the Impact of Event Scale-Revised (IES-R) score.

A total of 377 patients were enrolled in the study. The median time from symptom onset to clinical recovery and virological clearance was 79 (IQR 69-102) and 56 (IQR 47-74) days, respectively. A diagnosis of "long COVID" syndrome was made in 260/377 (69%) patients. The most common reported symptoms were fatigue (149/377, 39.5%), exertional dyspnoea (109/377, 28.9%), musculoskeletal pain (80/377, 21.2%) and "brain fog" (76/377, 20.2%). Anxiety symptoms were ascertained in 71/377 (18.8%) individuals, whereas 40/377 (10.6%) patients presented symptoms of depression. Post-traumatic stress disorder (defined by a pathological IES-R score) was diagnosed in one-third of patients (85/275, 31%). Female gender was independently associated with "long COVID" syndrome at multivariable analysis (AOR 3.3 versus males, 95%CI 1.8-6.2, p<0.0001).

Advanced age (AOR 1.03 for 10 years older, 95%CI 1.01-1.05, p=0.01) and active smoking (AOR 0.19 for former smokers vs active smokers, 95%CI 0.06-0.62, p=0.002) were also associated with a higher risk of "long COVID", while no association was found between severity of disease and "long COVID" (AOR 0.67 for Continuous Positive Airway Pressure CPAP/Non-Invasive Mechanical Ventilation NIMV/Orotracheal Intubation OTI vs no 02 therapy, 95%CI 0.29-1.55, p=0.85).

J o u r n a l P r e -p r o o f Introduction Over half of individuals affected by COVID-19 reports persisting symptoms after recovery from acute illness. These symptoms can endure up to 6-7 months and even longer [1] [2] [3] [4] [5] . Since the persistence of symptoms represents a health concern, this phenomenon was given the name of "long COVID" syndrome. In the UK, the National Institute for Health and Care Excellence (NICE) defined "long COVID" as the persistence of symptoms for more than 4 weeks after the onset of acute illness [6] [7] [8] . Ongoing physical symptoms include fatigue, muscle weakness, shortness of breath or cough, joint or chest pain, as well as difficulty in concentration and memory disorders; the latter two symptoms re-enter in a broader state of diminished mental capacity that may be described as "brain fog" [1, 4, [9] [10] [11] . As far as psychological manifestations are concerned, the most frequent are posttraumatic stress disorder (PTSD), depression, anxiety, obsessive-compulsive traits and insomnia [1, [12] [13] [14] [15] . Previous studies have not distinctly identified predictors of "long COVID" syndrome; factors found to have a correlation with "long COVID" so far were: increased length of acute illness, longer time from symptom onset to virological clearance and comorbidities [11, 16] . Increased COVID-19 severity and female gender as predicting factors are instead not equivocal findings [1, 4, 5, 8, 13, [17] [18] [19] [20] . Nevertheless, what emerges from preliminary data is the negative impact of "long COVID" on quality of life and its effects on patient work ability and social relationships [1, 4, 19] . Given the extent of such phenomenon, healthcare public resources will be utilised to face the issue even when the COVID-19 emergency status will end. It is therefore necessary to better understand the characteristics of "long COVID", its predictors and possible long-term sequelae. Furthermore, the likelihood of presenting ongoing symptoms might differ according to several factors (e.g. socioeconomic status or cultural background) that should therefore be identified.

We thus investigated the incidence of physical and/or psychological symptoms characterising the "long COVID" syndrome in female gender and to possibly identify predictors of "long COVID".

This is a single-centre prospective cohort study conducted at San Paolo Hospital in Milan, Italy.

Informed consent from all participants was obtained. The study was approved by the Ethical Committee Area 1, Milan (2020/ST/049 and 2020/ST/049_BIS, March 11 th 2020).

We enrolled adult patients that were evaluated at the post-COVID outpatient clinic, that was set up Not included in the study were patients who died during hospitalisation or after discharge, those who were not given a follow-up appointment because declined to participate or were unable to reach the hospital, and those who missed their appointment and were therefore lost to follow-up.

Patients who had been hospitalised for other medical issues and had a positive SARS-CoV-2 nasopharyngeal swab but remained asymptomatic for COVID-19, were also excluded from the study.

Follow-up implied:

-Repetition of nasopharyngeal swab for patients who were discharged with the indication to selfisolate since their upper respiratory swab was still positive at the time of discharge -Blood tests and comprehensive medical visit at 1 to 3 months and later at 6 months after virological clearance (namely a negative nasopharyngeal swab).

This study reports data about the first follow-up assessment at 1-3 months after virological clearance.

J o u r n a l P r e -p r o o f A trained nurse was in charge of taking blood samples, whereas a team of Infectious Diseases specialists and clinical psychologists were involved in visiting and interviewing participants. Patients were asked to self-report a detailed list of symptoms and signs, specifying whether they had resolved or were still ongoing. Moreover, they were invited to fill in two questionnaires: the Hospital Anxiety and Depression Symptoms (HADS) [21] and the Impact of Event Scale-Revised (IES-R) [22] . A comprehensive physical examination was performed by trained Infectious Diseases specialists.

Clinical psychologists, on the other hand, revised the questionnaires and identified symptoms of anxiety or depression and PTSD, by evaluating HADS and IES-R scores respectively.

Primary aim of the study was to assess the incidence of "long COVID" syndrome in females.

Secondary aim was to identify predictors of "long COVID" by multivariable logistic regression analysis.

Data of the acute phase of illness were collected. Disease severity was defined by the highest level of respiratory support required during hospitalisation (no oxygen therapy required, low-or high-flow oxygen therapy, Continuous Positive Airway Pressure CPAP, Non-Invasive Mechanical Ventilation NIMV and Orotracheal Intubation OTI). Treatments for COVID-19 included antiviral agents (remdesivir RDV or HIV protease inhibitors), hydroxychloroquine alone or in association with azithromycin, corticosteroids and immunomodulatory drugs (IL-6 receptor antagonists and JAK-STAT inhibitors). At follow-up, all patients underwent routine blood tests and a medical evaluation.

All patients were asked about the following signs and symptoms: anosmia, dysgeusia, fever, gastrointestinal symptoms, rest or exertional dyspnoea, fatigue, musculoskeletal pain, muscle weakness, "brain fog" manifestations (namely difficulties in attention or concentration and memory disorders).

HADS [21] was intended to measure anxiety and depression symptoms, whereas IES-R was used as a screening tool of PTSD [22] . A total HADS score higher than 8 denoted considerable symptoms of J o u r n a l P r e -p r o o f anxiety and depression, while a IES-R score above 33 was interpreted as highly suggestive for PTSD. "Long COVID" was defined as the persistence of 1 physical and/or psychological symptoms at follow-up [7] .

Data were presented as median and interquartile range (IQR) for quantitative parameters and absolute numbers and percentages for categorical variables. A Venn diagram was used to show possible correlations among physical and psychological symptoms characterizing "long COVID".

Comparison between the group of patients diagnosed with "long COVID" and that of patients who did not and between females and males was investigated by Mann-Whitney test and Chi-square or Fisher's exact test. The association between female gender and "long COVID" was analysed by Women were less frequently active smokers as compared to men. Furthermore, overall patients of female gender presented a milder form of disease, estimated as a lower proportion of OTI and a shorter LOS (Table 2 ). Blood tests at follow-up showed no significant alterations: C-reactive protein (CRP) and complete blood count (CBC) were normal for all patients, while D-dimer was still out of range in 28/377 (8%) patients without however any correlation with organ dysfunction (median pathological D-dimer was 399, IQR 310.7-579.2 ng/mL). In all 28 patients with elevated D-dimer at follow-up, levels were lower as compared to the acute phase of illness; however, 2 of these patients presented persisting dyspnoea and therefore underwent chest CT scan with contrast medium that excluded pulmonary thromboembolism. Figure 1b and 1c) .

The most common physical symptoms characterising "long COVID" were fatigue (149/377, 39.5%), exertional dyspnoea (109/377, 28.9%), musculoskeletal pain (80/377, 21.2%) and "brain fog"

(76/377, 20.2%) (Table 3a) . (Table 3b) . Interestingly, women were characterized by a higher proportion of most physical symptoms and all psychological symptoms, compared to males (Table   3 ).

At multivariable logistic regression analysis, female gender was associated with a 3-fold higher risk of "long COVID", also after adjustment for age, severity of illness, LOS, comorbidities, smoking, BMI and time from symptoms onset to virological clearance (Table 4 ). Other independent predictors of "long COVID" were advanced age and active smoking. Severity of disease, LOS and time to virological clearance were not associated with "long COVID" at univariable and multivariable analyses (Table 4 ).

The American Center for Disease Control (CDC) and the British NICE have identified symptoms that could persist for weeks or even months after recovery from COVID-19. How long these symptoms could endure for, possible risk factors for their persistence and the predisposing patient features are all aspects to be further elucidated [6] [7] [8] 17] . Our study reveals that:

The most common symptoms characterizing "long COVID" were both physical and psychological;

(ii) Females had a 3-fold higher risk of being diagnosed with "long COVID";

(iii) severity of disease and time to virological resolution were not associated with "long COVID";

The high incidence of "long COVID" within our cohort was similar to that previously reported: more than half of patients reported symptoms lasting more than two months after symptom onset [4, 5, 16, J o u r n a l P r e -p r o o f 18, 19] . Some symptoms are also commonly seen in other viral illnesses and both psychical and psychological sequelae have been described in MERS and SARS [12, [23] [24] [25] [26] [27] [28] [29] .

Literature data are not equivocal about the association between females and "long COVID": some preliminary studies have shown an increased prevalence of fatigue [24] or other symptoms among women [1, 5, 13, 16] , while in other studies no gender association was found [4, [18] [19] [20] . Differences in ethnicity, living country and possibly socio-economic status might explain such contrasting results.

Hormones may play a role in perpetuating the hyperinflammatory status of the acute phase even after recovery [30, 31] and a stronger IgG antibodies production in females in the early phase of disease has been reported; this could turn out in a more favourable outcome in women [32] , but might play a role as well in perpetuating disease manifestations. Furthermore, we might hypothesise that women are in general more attentive to their body and related distress.

Advanced age was associated with ongoing fatigue and musculoskeletal pain, or impairment in pulmonary functions, reflecting a decline in organ function and a slower ability to recover [1, 16] . As far as our finding that reported a weak association between obesity and "long COVID" is concerned, this was not confirmed in a previous study that however focused on persisting fatigue solely [24] .

Increased inflammation, defective adaptative immune responses, endothelial dysfunction and coagulation-related disorders are all phenomena that have been well described in obesity and might represent a plausible explanation to the link we observed between high BMI and "long COVID" [33] .

Finally, the relationship between smoking and "long COVID" has not been previously explored; the most frequent symptom reported by smokers was however shortness of breath, which possibly reflects an underlying pulmonary dysfunction.

We were expecting to find an association between severity of disease and residual symptoms, as reported by previous studies [1] . However, "long COVID" has been previously described also in not hospitalised patients diagnosed with a mild, self-limiting disease [6, [16] [17] [18] 24 ].

Our study has some limitations: a possible selection bias due to losses to follow-up; the limited sample size for patients with severe disease and females; the lack in validated tools to assess dyspnoea and fatigue and in information about the presence of the symptoms before the onset of acute infection.

The possible association between female gender and "long COVID" should be confirmed in larger populations and by means of a longer follow-up. The evaluation of our patients at six months still needs to be completed and this will certainly allow us to collect further data and build stronger evidence.

In conclusion, in our setting "long COVID" was a frequent long-term complication of COVID-19

and was diagnosed more frequently in women as compared to men. It was also commonly seen in patients who recovered from a mild disease form. Follow-up outpatient services are therefore needed in order to manage this syndrome and to better understand the possible association between symptoms and residual organ impairment, and their impact on patient quality of life. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Long COVID: let patients help define long-lasting COVID symptoms

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Persistent Symptoms in Patients After Acute COVID-19

Surviving COVID-19 in Bergamo Province: a post-acute outpatient re-evaluation

NICE guideline on long COVID

Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline

NICE guideline on long COVID

COVID-19: What do we know about "long COVID"?

Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

Follow-up of adults with noncritical COVID-19 two months after symptom onset

Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy

Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors

Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms

Post-traumatic stress disorder: A differential diagnostic consideration for COVID-19 survivors

Clinical sequelae of COVID-19 survivors in Wuhan, China: a singlecentre longitudinal study

Long-Term Effects of COVID-19

Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study

Sixty-Day Outcomes Among Patients Hospitalized With COVID-19

Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae

The hospital anxiety and depression scale

Long-term psychiatric morbidities among SARS survivors

Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis

Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection

Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study

Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study

Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors

COVID-19 pandemic and mental health consequences: Systematic review of the current evidence

The psychiatric sequelae of the COVID-19 pandemic in adolescents, adults, and health care workers

Sex differences in COVID-19: the role of androgens in disease severity and progression

Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities

A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex

Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning